The role of specific KRAS mutation types in response to treatment by EGFR inhibitors.
O. Fiala
No relevant relationships to disclose
M. Pesek
No relevant relationships to disclose
L. Benesova
No relevant relationships to disclose
B. Belsanova
No relevant relationships to disclose
M. Minarik
No relevant relationships to disclose